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acid transporters (FABPpm, FATP1, FATP4, and FATP6) are also induced to translocate. Insulin and
muscle contraction increased glucose transport and plasmalemmal GLUT4 independently and addi-
tively (positive control). Palmitate transport was also stimulated independently and additively by
insulin and by muscle contraction. Insulin and muscle contraction increased plasmalemmal FAT/
CD36, FABPpm, FATP1, and FATP4, but not FATP6. Only FAT/CD36 and FATP1 were stimulated in
an additive manner by insulin and by muscle contraction.
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In recent years it has been shown that fatty acids are trans-
ported into many tissues via a protein-mediated mechanism (for
review see [1]). A number of fatty acid transporters have been
identiﬁed, many of which are co-expressed in the same tissue.
Two key fatty acid transporters are fatty acid translocase (FAT/
CD36) and plasma membrane associated fatty acid-binding protein
(FABPpm), each of which has been shown to stimulate fatty acid
transport [1–3]. Chronically increased fatty acid transport rates
has been linked with a permanent relocation of FAT/CD36 to the
plasma membrane in type 2 diabetes (for review see [1]) and
diet-induced insulin resistance [4].
Acute regulation of protein-mediated fatty acid transport can
also occur. In skeletal muscle, contraction and insulin induce the
translocation of FAT/CD36 and FABPpm from an intracellular de-
pot(s) to the plasma membrane (for review see [1,5]). Tissue spec-
iﬁcity appears to occur, as in heart insulin induces the
translocation of FAT/CD36 but not FABPpm [1]. Even less is known
regarding the translocation of a family of fatty acid transport pro-
teins (FATP1-6), although their involvement in the regulation ofchemical Societies. Published by Efatty acid transport has been shown [6]. FATPs are expressed in a
tissue-speciﬁc manner [7,8], and in muscle tissues FATP1, 4 and
6 are co-expressed [7,9]. FATP1-null mice are resistant to diet-in-
duced insulin resistance [10]. Although FATP1 appears to be insulin
sensitive in muscle [11], it is not known whether insulin and/or
muscle contraction induce the translocation of FATP1, 4, or 6.
Metabolic challenges with insulin and muscle contraction/exer-
cise have revealed that skeletal muscle glucose transport can be
stimulated independently by insulin and by muscle contraction/
exercise, and additively when these stimuli are combined [12], as
these stimuli induce GLUT4 translocation to the sarcolemma from
insulin- and contraction-sensitive intracellular depots. In this man-
ner the uptake and utilization of glucose is elegantly controlled,
either to re-establish euglycemia after a meal or to increase sub-
strate provision when demand for this substrate is increased, such
as during exercise.
As with glucose, fatty acids are also cleared from the circulation
either after a meal [13] or when demand for this substrate is in-
creased with exercise [14]. Yet, it is not known (a) whether an in-
creased rate of uptake of fatty acids primarily requires an increase
in plasmalemmal FAT/CD36 or whether other fatty acid transport-
ers are also involved, and (b) whether muscle contraction and
insulin stimulate fatty acid transport and transporters in an addi-
tive manner. Therefore, in the present studies we have examinedlsevier B.V. All rights reserved.
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of muscle contraction and insulin on (i) the rates of fatty acid
transport into giant vesicles prepared from skeletal muscle and
(ii) on the appearance of fatty acid transporters (FAT/CD36, FAB-
Ppm, FATP1, FATP4 and FATP6) at the plasma membrane in re-
sponse to these stimuli. For reference purposes we also examined
the effects of these stimuli on insulin- and contraction-stimulated
glucose transport and sarcolemmal GLUT4.2. Materials and methods
2.1. Animals
We used 8–12 week old, overnight fasted male mice C57BL/6J.
They were bred on site, and housed in controlled temperature
and humidity conditions on a 12:12-h light–dark cycle. Animals
were provided with standard laboratory chow and water ad libi-
tum. Rates of glucose and fatty acid transport as well as plasma-
lemmal fatty acid transporters were examined in giant vesicles
prepared from hindlimb muscles of overnight fasted mice. There
were four experimental groups: control, insulin stimulation, mus-
cle contraction, or combined insulin and muscle contraction.
Experiments were approved by the committee on animal care at
the University of Guelph and were performed with anesthetized
mice (sodium pentobarbital (6 mg/100 g body wt ip; MTC Pharma-
ceuticals, Cambridge, ON, Canada).
2.2. Experimental treatments
For treatments other than control (no treatment), animals were
either (a) injected with insulin (Humulin, 1.0 U/kg body wt, i.p. (Eli
Lilly, Toronto, ON, Canada)), (b) muscles were induced to contract
(sciatic nerve stimulation; train delivery 100 Hz/3 s at 5 V, train
duration 200 ms, pulse duration 10 ms), or (c) muscles were ex-
posed simultaneously to the insulin and muscle contraction treat-
ments. After 15 min, hindlimb muscles were harvested. Tail vein
glucose concentrations were also measured (glucose monitor:
Ascensia Elite XL, Bayer Inc., Toronto, ON, Canada).
2.3. Giant sarcolemmal vesicles and substrate transport
Giant sarcolemmal vesicles were prepared from hindlimb mus-
cles immediately after harvest, as we have described previously in
detail elsewhere [15] and were used to determine substrate trans-
port rates and plasmalemmal proteins in the same preparation. An-
other rapid separation procedure [16] was used to visualize the
presence of fatty acid transporters at the sarcolemma and intracel-
lular depots. Protein concentrations were determined by the
bicinchoninic acid (BCA) assay, and vesicles were used immedi-
ately for fatty acid and glucose transport assays or stored at
80 C for Western blotting analyses.
Palmitate transport rates (15 s) into giant sarcolemmal vesicles
were determined in separate experiments, as described previously
[15,17–19], using unlabeled palmitate (14 lM) and radiolabeled
0.3 lCi [3H]-palmitate (GE Healthcare, Baie D’urfe, QC, Canada) in
a 0.1% bovine serum albumin solution. Glucose transport was
determined using unlabeled D-glucose (5 mM) and radiolabeled
0.3lCi [3H] D-glucose (GE Healthcare).
2.4. Western blotting
Transport proteins were detected on the plasma membrane of
the giant vesicles, and on subfractionated sarcolemmal and endo-
somal preparations by Western blotting as we have described pre-
viously [17]. Standard procedures (SDS–PAGE) were used toseparate proteins and transfer them onto PVDF membranes. There-
after, membranes were blocked in 7.5% BSA for 1 h, and then probed
overnight at 4 C with the antibodies against FAT/CD36 (sc13572),
FATP1 (sc25541), and FATP4 (sc5834) (each 1:500 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), FATP6 (1:1000, gift, Dr.
A. Stahl, Palo Alto Medical Foundation Research Institute, Palo Alto,
CA), FABPpm (1:30 000 dilution) was a gift from Dr. J. Calles-Escan-
don (Wake Forest University), GLUT4 (1:4000 dilution; Millipore,
Temecula, CA, USA) and monocarboxylate transporter 1 (MCT1,
1:3000; gift from Dr. H. Hatta, University of Tokyo). Blots were de-
tected using enhanced chemiluminescence (Perkin Elmer Life Sci-
ence, Boston, MA) and quantiﬁed by densitometric analyses
(ChemiGenius2 Bioimaging, SynGene, Cambridge, U.K.). All blots
were stained with Ponceau-S to ensure equal loading of protein.
2.5. Statistics
Data were analyzed using analysis of variance and Fisher’s LSD
post-hoc test when appropriate. All data are reported as
means ± S.E.M.3. Results
Blood glucose was monitored to ensure a reduction with insulin
treatments. Basal glucose concentrations were 6.48 ± 0.09 mM.
This was not reduced by muscle contraction, but was reduced by
the insulin (70%) and the insulin + contraction (69%) treatments.
3.1. Glucose transport and GLUT4
Muscle contraction or insulin increased the rates of glucose
transport 2.5- and 3.6-fold respectively (Fig. 1A). When the two
stimuli were combined, glucose transport was increased 5-fold
(Fig. 1A). Plasmamembrane GLUT4 was upregulated whenmuscles
were stimulated with contraction (+76%), insulin (+154%) and by
the combined contraction and insulin stimulation (+277%)
(Fig. 1B). As a positive control plasma membrane MCT1, which is
not translocated [20,21], was not altered during these experiments
(Fig. 1C). These experiments conﬁrm that the insulin and muscle
contraction induced the well-known independent and additive ef-
fects on glucose transport and GLUT4 translocation.
3.2. Effects of insulin and muscle contraction on fatty acid transport
and fatty acid transporters
Palmitate transport was increased by muscle contraction (1.7-
fold), by insulin (2.9-fold), and by the combination of contraction
and insulin (3.5-fold) (Fig. 2A). Concomitantly, plasma membrane
fatty acid transporters were increased with muscle contraction
(FAT/CD36 +55%; FABPpm +62%; FATP1 +61%; FATP4 +66%), insulin
(FAT/CD36 +78%; FABPpm +61%; FATP1 +84%; FATP4 +60%), and
with combined muscle contraction and insulin (FAT/CD36 +179%;
FABPpm +85%; FATP1 +125%; FATP4 +89%) (Fig. 2B–E). Subfraction-
ation of muscles showed that these foregoing transporters were in-
duced to translocate from intracellular depots to the plasma
membrane (Fig. 3). Plasma membrane content of FATP6 was not al-
tered by insulin or muscle contraction (Fig. 2F), and therefore their
combined effect on plasmalemmal FATP6 was not examined.
3.3. Additive effects of insulin and muscle contraction on glucose and
fatty acid transport, GLUT4 and fatty acid transporters
For glucose transport the combined effects of muscle contrac-
tion and insulin were quite comparable, as with the combined
stimuli (insulin + contraction) glucose transport was almost identi-
Fig. 1. Effects of muscle contraction, insulin and muscle contraction + insulin on rates of glucose transport (A), and plasma membrane GLUT4 (B) and MCT1 (C)
(means ± S.E.M.). *P < 0.05, muscle contraction, insulin or muscle contraction + insulin vs control; **P < 0.05, insulin vs muscle contraction; ***P < 0.05, muscle
contraction + insulin vs insulin.
Fig. 2. Effects of muscle contraction, insulin and muscle contraction + insulin on rates of palmitate transport (A), and plasma membrane FAT/CD36 (B), FABPpm (C), FATP1
(D), FATP4 (E) and FATP6 (F) (means ± S.E.M.). ND: not determined, as FATP6 did not respond to either insulin or muscle contraction. *P < 0.05, muscle contraction, insulin or
muscle contraction + insulin vs control; **P < 0.05, insulin vs muscle contraction; ***P < 0.05, muscle contraction + insulin vs insulin.
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(Fig. 4A). Plasmalemmal GLUT4 was 20% greater when the two
stimuli were applied simultaneously, compared to when their
independent effects were summed (Fig. 4B).Palmitate transport was also quite similar when the two stimuli
were applied simultaneously (95%) compared to the sum of their
independent effects (Fig. 5A). However, this was not the case for
some of the fatty acid transporters. For FAT/CD36 and FATP1 the
Fig. 3. Plasmalemmal and intracellular GLUT4 and fatty acid transporters in
control, insulin-stimulated, contraction stimulated, and insulin + contraction-stim-
ulated muscles. Representative blots of two independent experiments.
Fig. 4. Comparison of independent and combined effects of insulin stimulation and
muscle contraction on glucose transport (A) and plasma membrane GLUT4 (B).
Summed: insulin-stimulated net increase over control + contraction-stimulated net
increase over control. Combined: net increase over control when insulin and muscle
contraction were administered simultaneously. Insulin stimulation: ; muscle
contraction: h; insulin + muscle contraction combined: j.
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additive, since with the combined treatment (insulin + contrac-
tion) the plasmalemmal levels of these proteins were either some-Fig. 5. Comparison of independent and combined effects of insulin stimulation and mu
FABPpm (C), FATP1 (D), and FATP4 (E). Summed: the independent effects of insulin and
subtracted). Combined: insulin and muscle contraction were administered simultaneous
or muscle contraction their combined effects were not examined. Insulin stimulation:what greater (FAT/CD36 +35%, Fig. 5B) or only slightly lower
(FATP1 14%, Fig. 5D) when compared to the sum of independent
insulin and contraction effects. In contrast, plasmalemmal FABPpm
and FATP4 were not increased additively, since with the combined
treatment (insulin + contraction) the plasmalemmal FABPpm
(31%, Fig. 5C) and FATP4 (37%, Fig. 5E) levels remain well below
that of the sum of the independent insulin and contraction effects.
4. Discussion
The present study was designed to examine (a) whether fatty
acid transporters other than FAT/CD36 could be induced to trans-
locate to the plasma membrane, and (b) whether the effects of
insulin and muscle contraction were additive with respect to fatty
acid transport and transporter translocation. The following novel
information was revealed in these present studies: (i) many fatty
acid transporters (FATP1, FATP4 and FABPpm) besides FAT/CD36
were induced to translocate to the sarcolemma, either by insulin
or by muscle contraction, (ii) FATP6 failed to respond these stimuli,
(iii) fatty acid transport was increased in an additive manner when
insulin and muscle contraction were combined, but (iv) only two of
the fatty acid transporters (FAT/CD36 and FATP1) were induced to
translocate to the sarcolemma in an additive manner. These stud-
ies indicate (a) that increases in fatty acid transport induced by
metabolic stimuli are attributable to the concomitant translocation
of a number of fatty acid transporters, and (b) just as for GLUT4,
[22] there appear to be insulin-sensitive and contraction-sensitive
intracellular depots for FAT/CD36 and FATP1, but not for FABPpm,
FATP4 or FATP6.
4.1. Glucose and fatty acid transport into giant vesicles
It was not surprising that insulin and muscle contraction each
increased the rates of glucose transport, as has long been known
[12,23]. Recently, we have shown that these stimuli also increase
the rate of fatty acid transport (for review see [1]). For these
purposes we have used giant sarcolemmal vesicles, just as in thescle contraction on palmitate transport (A) and plasma membrane FAT/CD36 (B),
muscle contraction are added together (from each of these the control data were
ly (the control data were subtracted). Since FATP6 failed to respond to either insulin
; muscle contraction: h; insulin + muscle contraction combined: j.
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transport across the plasma membrane, as fatty acids are not
metabolized further [1]. Despite an early report to the contrary
[24], we have found that these giant vesicles are suitable for
detecting either insulin- or contraction-stimulated glucose trans-
port ([25] and present study). Giant vesicles offer several addi-
tional advantages, namely, they are 100% right side out, which
may well be important when examining fatty acid transport, and
fatty acid transport rates and plasmalemmal fatty acid transporters
can be determined in the same preparation.
4.2. Fatty acid transport and fatty acid transporters
Long chain fatty acids are taken up largely via a protein-medi-
ated mechanism [1,8]. Indeed, for the fatty acid transporters exam-
ined in this study it has been shown that each one facilitates fatty
acid uptake [2,3,6,26–28]. Yet, it is uncertain why a number of fatty
acid transporters are necessarily co-expressed in metabolic tissues.
It has been suggested that these proteins may interact with each
other, but as yet there is only limited evidence for this [1]. It is
known that different fatty acid transporters exhibit different fatty
acid transport capacities [6,28] and possibly fatty acid speciﬁcity
[9]. Presumably, our present work and others [6] indicates that
FATP6 is of limited metabolic signiﬁcance.
4.3. Insulin-stimulated fatty acid transport and transporter
translocation
The insulin-stimulated increase in plasmalemmal FAT/CD36 has
been shown previously in skeletal muscle and in cardiac myocytes
(for review see [1]), while insulin-induced FATP1 translocation
occurs in muscle (present study and [11]) but not the heart [1].
Similarly, insulin-stimulated FABPpm translocation may also be
tissue-speciﬁc, as this protein is insulin sensitive in skeletal muscle
but not in cardiac myocytes [1]. Ours is the ﬁrst study to observe
that insulin also induces FATP4 translocation in mammalian
muscle. While it may be presumed that insulin-stimulated translo-
cation of fatty acid transporters occurs via the insulin signaling
pathway, as has been shown for FAT/CD36 [1], this assumption
may not be valid. Studies in our laboratory suggest that FABPpm
and FATP4 may be induced to translocate by insulin via a route
other than the PI3-kinase-Akt signalling pathway [29].
4.4. Contraction-stimulated fatty acid transport and transporter
translocation
The contraction-stimulated increase in skeletal muscle plasma-
lemmal FAT/CD36 and FABPpm has been shown previously in skel-
etal muscle [5,17,30]. This is the ﬁrst report to show that muscle
contraction also induces the translocation of FATP1 and FATP4.
The signalling pathways involved in inducing fatty acid transporter
translocation are unknown, although we have shown that activa-
tion of AMPK induces the translocation of FABPpm and FAT/CD36
[1]. Preliminary studies in our group suggests that Akt2 activation
may also be necessary to for contraction-induced FAT/CD36 and
FATP1 translocation, whereas this kinase appears not to be re-
quired for contraction-induced FABPpm and FATP4 translocation
[29].
4.5. Additive effects of insulin and muscle contraction on fatty acid
transport and transporter translocation
It is now well known that insulin and muscle contraction stim-
ulate glucose transport in an additive manner [22,31], and this was
observed in the present study. Here we report for the ﬁrst time that
fatty acid transport is also increased in an additive manner whenmuscles are stimulated simultaneously with insulin and contrac-
tion. The additive effects of insulin and muscle contraction on glu-
cose transport are attributable to the concomitant additive
increases in plasma membrane GLUT4 ([22] and present study),
as GLUT4 is recruited from distinct insulin-, and contraction-sensi-
tive intracellular depots [22]. Presumably, the additive increases in
plasmalemmal FAT/CD36 and FATP1, induced by the simultaneous
stimulation with insulin and muscle contraction, suggests that
there are also distinct insulin-, and contraction-sensitive intracel-
lular depots for these two transporters. However, an additive effect
was not observed for FABPpm or FATP4, despite the fact with either
the insulin or muscle contraction treatments the sarcolemmal con-
tent of each of these two transporters was increased substantially
(62–89%). We interpret this to suggest that each has a single intra-
cellular depot that is targeted by both insulin-mediated and con-
traction-mediated signals.
4.6. Relative effectiveness of fatty acid transporters and difﬁculties
comparing between experimental preparations
Studies in FAT/CD36 null mice [3,32] and FATP1-null mice [11]
indicate that these proteins are necessary to facilitate fatty acid up-
take. Comparable studies are not available for either FABPpm or
FATP4, although it has been shown that deletion of FATP4 results
in early embryonic lethality [33,34].
The present studies cannot reveal which of the fatty acid trans-
port proteins is the most important. To address this problem, a
number of studies have examined the roles and transport capaci-
ties of fatty acid transporters in cell lines. This has yielded contra-
dictory observations among different cell lines and/or with
observations in metabolically important tissues in vivo. For exam-
ple, transport capacities among FATPs can differ substantially, as
revealed by overexpression [6,9,35] or knockdown studies [36],
but there is little agreement as to which FATP is most effective.
In yeast, FATP4 exhibited 1.7- and 3-fold greater fatty acid trans-
port effectiveness compared to FATP1 and FATP2, respectively,
while no fatty acid transport capacities were attributable to FATP3,
5 and 6 [6]. In contrast, in HEK293 cells the FATP6 transport capac-
ity was 3- and 6.5-fold greater than FATP1 and FATP4, respectively
[9], while in 3T3-L1 adipocytes a fatty acid transport role was evi-
dent only for FATP1 but not FATP4 [36]. This group [37] has linked
the role of FATP4-mediated fatty acid uptake to inducing an in-
crease in fatty acid esteriﬁcation [37]. In contrast, in mammalian
muscle we ﬁnd that FATP1 and FATP4 each have a fatty acid trans-
port role at the plasma membrane, with that of FATP4 being com-
parable to FAT/CD36 and greater than that of either FATP1 and
FABPpm [28]. Clearly, all these studies have failed to reach a con-
sensus on the regulation and effectiveness of selected fatty acid
transporters.
These different and apparently conﬂicting ﬁndings among the
foregoing studies are perhaps not too surprising. This likely reﬂects
the use of diverse cell lines or different types of mammalian tis-
sues. Different cell lines often have ill-deﬁned metabolic machin-
ery for fatty acid uptake and metabolism, yet it seems to be
frequently assumed that an available cell line is a suitable model
for examining fatty acid transport and metabolism. This is ques-
tionable. Several recent reports indicate that fatty acid transport
cannot be adequately examined in some cells because these appear
to lack accessory proteins that may be involved in fatty acid trans-
port [38,39]. In addition, extrapolation of results from cultured
cells to metabolically important tissue in vivo may also be prob-
lematic, as cells and mammalian tissues likely have different
requirements for fatty acid utilization, and their regulation of fatty
acid uptake may also differ. For example, the mechanisms regulat-
ing the acute contraction-induced upregulation of fatty acid trans-
port and oxidation, such as occurs in heart and skeletal muscle, is
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ble to examine mechanisms of fatty acid transport and transport-
ers in mammalian tissues that have a well-known requirement
for utilizing fatty acids, either for energy provision (muscle and
heart) or storage and release (adipocytes). It would not be surpris-
ing if these different functions by different tissues may well rely on
tissue-speciﬁc fatty acid transporter(s) and unique sensitivities to
physiologic/metabolic stimuli involving distinct signalling sys-
tems. It is difﬁcult to envision that all of the tissue diversity con-
cerning fatty acid metabolism in vivo can be captured adequately
in any one given experimental model. While cell lines can provide
unique information at times, extrapolation to situations and tis-
sues in vivo requires considerable caution. It is therefore also
advantageous to examine a process such as fatty acid transport
in the particular mammalian tissue of interest.
4.7. Summary
We have found that either insulin or muscle contraction induce
the translocation of a number of fatty acid transporters, including
FAT/CD36, FABPpm, FATP1 and FATP4. Notably, FATP6 is insensi-
tive to these stimuli. Only FAT/CD36 and FATP1 were stimulated
in an additive manner by the simultaneous administration of insu-
lin and muscle contraction, suggesting that these transporters re-
side in insulin-, and contraction-sensitive intracellular depots. In
view of recent evidence that FAT/CD36 has a far greater transport
capacity than FATP1, this transporter may be the key transporter in
mammalian skeletal muscle.
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